Post-Renal Transplant Thrombotic Thrombocytopenic Purpura (TTP): Attributable to Immunosuppression or Graft Rejection? Report of Three Cases and Literature Review
Abstract
The immunomodulatory drug FK-506 (Tacrolimus) is a calcineurin inhibitor that, as such, indirectly inhibits the transcription of a gene encoding interleukin 2, a cytokine that is vital to the immune response process. Since its introduction in 1987, sporadic reports have appeared describing the development of thrombotic thrombocytopenic purpura (TTP) - or a similar syndrome - in patients taking this drug. Sirolimus (Rapamune) is another immunomodulatory drug with a more favorable side-effects profile than calcineurin inhibitors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 25, 2005
- Accession Number
- ADA429608
Entities
People
- Joseph P. Pelletier
- Oluwole Fadare
- Yanyun Wu
Organizations
- Yale University